Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 10/20 | 0.62 |
| ▸ | EHMT1 | Q9H9B1 | 6/20 | 0.62 |
| ▸ | KMT5A | Q9NQR1 | 8/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385857 | 0.92 | EHMT2 (0.61) | EHMT2EHMT1KMT5A | |
| SCHEMBL25204671 | 0.92 | EHMT2 (0.61) | EHMT2EHMT1KMT5A | |
| SCHEMBL29382553 | 0.91 | EHMT2 (0.58) | EHMT2EHMT1KMT5A | |
| SCHEMBL25224615 | 0.91 | EHMT2 (0.58) | EHMT2EHMT1KMT5A | |
| SCHEMBL29382624 | 0.88 | EHMT1 (0.58) | EHMT2EHMT1KMT5A | |
| SCHEMBL25220750 | 0.88 | EHMT1 (0.58) | EHMT2EHMT1KMT5A | |
| SCHEMBL29385222 | 0.85 | EHMT2 (0.65) | EHMT2EHMT1KMT5A | |
| SCHEMBL25201637 | 0.85 | EHMT2 (0.65) | EHMT2EHMT1KMT5A | |
| SCHEMBL25236608 | 0.85 | EHMT2 (0.69) | EHMT2EHMT1KMT5A | |
| SCHEMBL29385395 | 0.85 | EHMT2 (0.69) | EHMT2EHMT1KMT5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116323587-A | Small molecules for autoimmune diseases and cancer treatment | 阿索斯治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4192826-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | Athos Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11485728-B2 | Small molecules for the treatment of autoimmune diseases and cancer | ATHOS THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220073498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2022031939-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | EHMT2 1523/4885EHMT1 1748/4885KMT5A 2696/4885 |
| US-11485728-B2 | Small molecules for the treatment of autoimmune diseases and cancer | SSB, HLA-DRB1, UACA | EHMT2 1523/4885EHMT1 1748/4885KMT5A 2696/4885 |
| US-20220073498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | EHMT2 1523/4885EHMT1 1748/4885KMT5A 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.